The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature

Bianca Laura Bernardoni,Ilaria D'Agostino,Fabio Scianò,Concettina La Motta
DOI: https://doi.org/10.1080/13543776.2024.2412573
2024-10-13
Expert Opinion on Therapeutic Patents
Abstract:Introduction Aldose reductase (AKR1B1, EC: 1.1.1.21) is a recognized target for the treatment of long-term diabetic complications since its activation in hyperglycemia and role in the polyol pathway. In particular, the tissue-specificity of AKR1B1 expression makes the design of the traditional Aldose Reductase Inhibitors (ARIs) and the more recent Aldose Reductase Differential Inhibitors (ARDIs) exploitable strategies to treat pathologies resulting from diabetic conditions.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?